Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeremy Green, Redmile Group Boost Position in Amicus Therapeutics, Inc. (FOLD)

Jeremy Green‘s Redmile Group has significantly surged its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD), a new filing with the SEC revealed. Redmile currently holds over 8.6 million shares of the company, the passive stake amassing 15.14% of the company’s common stock. The position has been increased from around 2.5 million reported by Redmile in its latest 13F.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD), has been down by 9% since the beginning of the year. Recently the company disclosed that it received the global rights to develop and sell  the investigational pharmacological chaperone migalastat HCl, under an agreement with GlaxoSmithKline plc (ADR) (NYSE:GSK).  Also, under the terms of the same agreement, GSK will invest $3.0 million via an equity investment.

In the third quarter, the company reported revenue of $39,000. Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted a net loss of $14.6 million, equal to $0.29 per share, versus a loss of $16.3 million in the same period of last year.

Among large shareholders of the company, we can mention William Leland Edwards’ Palo Alto Investors, which in its last 13F reported holding 4.6 million shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD). The value of the stake amounts to $10.7 million. Sound Energy Partners, managed by Anthony Giammalva reported ownership of 595,200 shares, worth $1.4 million, and Chuck Royce’s Royce & Associates owns 515,700 shares, with a total value of $1.2 million.

Redmile Group reported, in its latest 13F, holding 271,500 shares of Actavis plc (NYSE:ACT), the value of the position amounting to $39.1 million, which is the largest in its equity portfolio. In Amgen, Inc. (NASDAQ:AMGN), Redmile owns a $38.7 million stake, which amasses 345,700 shares. The third-largest position in the fund’s equity portfolio, is St. Jude Medical, Inc. (NYSE:STJ), in which Redmile reported ownership of 658,000 shares, worth $35.3 million.

Disclosure: none

Recommended Reading:

Tontine Asset Management Sells Patrick Industries (PATK) and Westmoreland Coal Company (WLB) Shares

Prescott Group Capital Management Asks PharmAthene, Inc. (PIP) Shareholders to Vote Against Merger With Theraclone

Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher